Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
6-month Follow-up
12%
Acuity Score
12%
Aquaporin-4 (AQP4)
50%
Best-corrected Visual Acuity
50%
Demyelinating Optic Neuritis
100%
Early Initiation
12%
Increasing Trends
12%
Limited Value
12%
Logarithm of the Minimum Angle of Resolution
50%
Logistic Regression
12%
Methylprednisolone
12%
Methylprednisolone Pulse Therapy
12%
Myelin Oligodendrocyte Glycoprotein
25%
Myelin Oligodendrocyte Glycoprotein Antibody
12%
No Significant Difference
12%
Optic Neuritis
100%
Plasma Exchange
100%
Plasma Exchange Therapy
37%
Prospective Cohort Study
100%
Receiver Operating Characteristic Curve
12%
Serum Antibody
100%
Single Center
12%
Two-level
12%
Visual Outcome
25%
Medicine and Dentistry
Aquaporin 4
27%
Aquaporin 4 Antibody
9%
Best Corrected Visual Acuity
36%
Drug Megadose
9%
Logistic Regression Analysis
9%
Methylprednisolone
9%
Myelin Oligodendrocyte Glycoprotein
27%
Optic Neuritis
100%
Plasma Exchange
100%
Prospective Cohort Study
100%
Prospective Study
9%
Biochemistry, Genetics and Molecular Biology
Antibody Blood Level
100%
Aquaporin 4
36%
Best Corrected Visual Acuity
36%
Blood Plasma
100%
Drug Megadose
9%
Methylprednisolone
9%
Myelin Oligodendrocyte Glycoprotein
27%
Prospective Cohort Study
100%
Prospective Study
9%
Immunology and Microbiology
Antibody Blood Level
100%
Aquaporin
27%
Aquaporin 4 Antibody
9%
Best Corrected Visual Acuity
36%
Blood Plasma
100%
Drug Megadose
9%
Methylprednisolone
9%
Myelin Oligodendrocyte Glycoprotein
27%
Optic Neuritis
100%
Neuroscience
Aquaporin 4
27%
Aquaporin 4 Antibody
9%
Blood Plasma
100%
Methylprednisolone
9%
Myelin Oligodendrocyte Glycoprotein
27%
Optic Neuritis
100%